PMID: 7535752Mar 29, 1995Paper

Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma

International Journal of Cancer. Journal International Du Cancer
S MoriA Uchida

Abstract

We treated a murine osteosarcoma cell line, LM8, which preferentially metastasizes to the lungs, with a new angiogenesis inhibitor, TNP-470, to evaluate the efficacy of this compound in the suppression of pulmonary metastasis of osteosarcoma. In an in vivo experiment, tumor cells were inoculated i.v. into C3H mice, and TNP-470 or vehicle alone (control group) was administered s.c. every day for 3 weeks. In the TNP-470-treated groups, both the number of pulmonary metastatic nodules and the lung wet weight were significantly reduced in a dose-dependent manner. Similarly, vascular density in the metastatic tumors estimated by immunohistochemical staining with anti-von-Willebrand factor antibody as an endothelial marker were significantly reduced. No severe side-effects were found. In an in vitro experiment, viable tumor cells were counted after 3 days' treatment with TNP-470. The 50% inhibitory concentration was 0.6 ng/ml for LM8, which was more sensitive than other tumor cells previously reported. Our results show that TNP-470 suppresses the pulmonary metastasis of LM8 and suggest that both its anti-angiogenic activity and cytostatic activity towards LM8 are responsible for the antitumor effect.

References

Feb 14, 1991·Biochemical and Biophysical Research Communications·M KusakaJ Folkman
Aug 12, 1971·The New England Journal of Medicine·J Folkman
May 27, 1982·Nature·S Taylor, J Folkman
Jan 10, 1980·Nature·G Poste, I J Fidler
Mar 1, 1993·Journal of Pediatric Surgery·H Brem, J Folkman
Mar 1, 1993·Journal of Neurosurgery·Y TakamiyaR L Martuza

❮ Previous
Next ❯

Citations

Jan 13, 2006·Cancer Immunology, Immunotherapy : CII·Yoshiteru NakamuraNobuyuki Terada
Feb 14, 2006·Clinical & Experimental Metastasis·Ryota TomodaAtsumasa Uchida
Dec 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V Castronovo, D Belotti
Aug 6, 2000·British Journal of Haematology·M MinischettiA F Dammacco
Mar 24, 1998·Annual Review of Medicine·B R Zetter
May 1, 2013·American Journal of Veterinary Research·Valery F ScharfDietmar W Siemann
Dec 1, 2001·Expert Opinion on Biological Therapy·T G Zogakis, S K Libutti
Aug 10, 2000·Neoplasia : an International Journal for Oncology Research·D RibattiF Dammacco
Aug 10, 2013·Cancer Medicine·Hideki KitajimaRyuichi Ueoka
Jul 14, 2006·Critical Reviews in Oncology/hematology·Eugene T H EkPeter F M Choong
Feb 1, 1997·The Journal of Urology·Y TanakaR Oyasu
Sep 13, 2016·Laboratory Investigation; a Journal of Technical Methods and Pathology·Di YangTatsuji Haneji
Feb 15, 2001·Japanese Journal of Cancer Research : Gann·H KatoT Yoshiki
May 15, 2004·American Journal of Veterinary Research·James P FareseJamie M Baldwin
Dec 7, 2013·Expert Review of Anticancer Therapy·Nataraj Vijayamurugan, Sameer Bakhshi
May 13, 1999·International Journal of Experimental Pathology·P Gervaz, C Fontolliet
Feb 5, 2003·Clinical Orthopaedics and Related Research·Takeo TsunemiSeiichi Ishii
May 11, 2004·Biological & Pharmaceutical Bulletin·Kosuke Shimizu, Naoto Oku
Aug 25, 2000·American Journal of Physiology. Lung Cellular and Molecular Physiology·M JakkulaS H Abman
Mar 11, 2005·Expert Opinion on Therapeutic Targets·Kosuke ShimizuNaoto Oku
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Etmar BulkCarsten Müller-Tidow
Nov 1, 1996·Current Problems in Surgery·J A RothR S Benjamin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.